Evidence map›Paper›PMID 41849596›Full record

ArticleScience advances2026

Transforming cisplatin into targeted photothermal chemotherapeutics through the platinum-phosphate coordination within a hyaluronan nanogel.

Yiyi Zhang, Huimin Wang, Hua Guo, Xiaorong Gou, Xinxin Hao, Jiayi Li, Hong Deng, Weiqi Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yiyi ZhangState Key Laboratory of Complex Severe and Rare Diseases, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100005, P. R. China.ORCID 0009-0006-1021-1735
Huimin WangState Key Laboratory of Complex Severe and Rare Diseases, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100005, P. R. China.ORCID 0009-0002-3214-2700
Hua GuoState Key Laboratory of Molecular Oncology and Department of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P. R. China.
Xiaorong GouState Key Laboratory of Complex Severe and Rare Diseases, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100005, P. R. China.
Xinxin HaoState Key Laboratory of Complex Severe and Rare Diseases, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100005, P. R. China.
Jiayi LiState Key Laboratory of Complex Severe and Rare Diseases, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100005, P. R. China.
Hong DengState Key Laboratory of Complex Severe and Rare Diseases, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100005, P. R. China.
Weiqi ZhangState Key Laboratory of Complex Severe and Rare Diseases, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100005, P. R. China.ORCID 0000-0003-4315-6809

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cisplatin's (Cis's) antitumor efficacy is limited by dose-dependent toxicity due to nonspecific tissue distribution. While targeted Cis delivery and combination therapies boost therapeutic efficacy, developing multifunctional yet simplified formulations remains challenging. Inspired by the Cis's interaction with DNA, here, we transformed Cis into a reversible photothermal agent through the platinum-phosphate (Pt-phos) interaction within a hyaluronan (HA) nanogel (named as HA/PtP) to afford synergistic photothermal therapy (PTT) and chemotherapy. The HA/PtP nanogel exhibits near infrared absorption and 32.08% photothermal conversion efficiency, and degrades to release Cis through the reversible Pt-phos interaction under acidic conditions. Leveraging HA's intrinsic CD44 targeting, HA/PtP nanogel simultaneously enables highly efficient PTT and targeted chemotherapy in 4T1 breast tumor xenografts. Moreover, HA/PtP-based PTT successfully mimics hyperthermic intraperitoneal chemotherapy (HIPEC) but with alleviated Cis toxicity in MC38 metastatic mouse model. This HA/PtP nanogel represents a rationally designed Cis nanomedicine integrating the PTT with self-targeting and facile preparation.

Indexed as

Antineoplastic AgentsCisplatinHyaluronic AcidNanogelsPhosphatesPhotothermal TherapyPlatinumAnimalsCell Line, TumorFemaleHumansMiceXenograft Model Antitumor AssaysAntineoplastic AgentsCisplatinHyaluronic AcidNanogelsPhosphatesPlatinum

Identifiers

PMID41849596
PMCPMC12998518

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.